Acute Coronary Syndrome | Telmisartan Versus Ramipril After Acute Coronary Syndrome

Acute Coronary Syndrome research study

What is the primary objective of this study?

The purpose of this study is to compare the antinflammatory and endothelial progenitor cell (EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute coronary syndrome

Who is eligible to participate?

Inclusion Criteria: - Biochemical evidence of myocardial infarction as indicated by elevation of cTnT, - presence of ECG ischemic changes, - angiographic evidence of a primary coronary event, such as plaque erosion and/or rupture, fissuring, or dissection at coronary angiography, - successful coronary revascularization of at least one culprit coronary vessel. Exclusion Criteria: - Age>80 years, current ACE inhibitor or ARB treatment, - ejection fraction <35%, infarction secondary to ischemia due to an imbalance of O2 supply and demand, - ECG abnormalities that could affect the recognition of ST segment shift, - recent or chronic infective or inflammatory diseases, - malignancy, and myocardial infarction, - surgery or trauma in the previous month.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Acute Coronary Syndrome

Myocardial Infarction

Coronary Disease

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:TELMISARTAN80 mg daily

Drug:RAMIPRIL5 mg daily

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

RTwenty-five patients assigned to ramipril 5 mg daily

TTwenty-five patients assigned to Telmisartan 80 mg daily

Study Status

Unknown status

Start Date: November 2007

Completed Date: November 2008

Phase: Phase 4

Type: Interventional


Primary Outcome: High sensitivity C-Reactive Protein

Secondary Outcome: Endothelial Progenitor Cells

Study sponsors, principal investigator, and references

Principal Investigator: Italo Porto, MD, PhD

Lead Sponsor: Catholic University of the Sacred Heart


More information:

Biasucci LM, Lombardi M, Piro M, Di Giannuario G, Liuzzo G, Crea F. Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina. Heart. 2005 May;91(5):670-1.

Liakishev AA. [Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial]. Kardiologiia. 2008;48(5):72. Russian.

Discuss Ramipril